Allan Lipton Selected Research

Neoplasm Metastasis (Metastasis)

09/2008	Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a National Medical claims database.
07/2008	Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
01/2008	Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
10/2007	Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
09/2007	Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
07/2007	Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
01/2007	Treatment of bone metastases and bone pain with bisphosphonates.
06/2006	Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
04/2006	Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases.
02/2006	A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
11/2005	Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
08/2005	Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
09/2004	Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
10/2003	Biochemical markers and skeletal metastases.
02/2003	A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
02/2002	Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.

Articles by Research Topic

Disease

16	Neoplasm Metastasis (Metastasis) 09/2008 - 02/2002
13	Breast Neoplasms (Breast Cancer) 09/2008 - 03/2002
5	Neoplasms (Cancer) 09/2008 - 07/2002
4	Multiple Myeloma 03/2007 - 09/2002
4	Carcinoma (Carcinomatosis) 07/2005 - 02/2003
2	Bone Resorption 07/2008 - 08/2005
2	Prostatic Neoplasms (Prostate Cancer) 08/2007 - 06/2006
2	Pain (Aches) 01/2007 - 04/2006
2	Urogenital Neoplasms 06/2006 - 11/2005
2	Renal Cell Carcinoma (Grawitz Tumor) 09/2004 - 09/2003
1	Lung Neoplasms (Lung Cancer) 03/2008
1	Bone Diseases (Bone Disease) 03/2008
1	Disease Progression 07/2005
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2004

Drug/Important Bio-Agent (IBA)

10	zoledronic acid (zoledronate)FDA Link 09/2008 - 08/2003
7	DiphosphonatesIBA 01/2008 - 09/2002
4	HormonesIBA 08/2007 - 03/2002
3	Epidermal Growth Factor Receptor (EGF Receptor)IBA 02/2008 - 02/2003
2	Tissue Inhibitor of Metalloproteinase-1IBA 06/2008 - 05/2007
2	denosumabIBA 10/2007 - 02/2006
2	Biological Markers (Surrogate Marker)IBA 03/2007 - 10/2003
2	docetaxel (Taxotere)FDA Link 08/2003 - 02/2003
2	OsteoprotegerinIBA 02/2003 - 07/2002
1	trastuzumab (Herceptin)FDA Link 09/2008
1	Aromatase (CYP19)IBA 06/2008
1	Tamoxifen FDA LinkGeneric 06/2008
1	letrozole (Femara)FDA Link 06/2008
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2008
1	Aromatase InhibitorsIBA 01/2008
1	RANK LigandIBA 02/2006
1	celecoxib (Celebrex)FDA Link 12/2004
1	gemcitabine FDA Link 12/2004
1	irinotecan (Camptosar)FDA LinkGeneric 12/2004
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2003
1	Messenger RNA (mRNA)IBA 02/2003
1	collagen type I trimeric cross-linked peptideIBA 02/2002
1	Collagen Type I (Type I Collagen)IBA 02/2002